Condition
Acute Respiratory Infection (ARI)
Acute respiratory infections, such as colds, flu and bronchitis, are mostly viral infections of the nose, throat and airways, where the immune response brings on inflammation, extra mucus and cough. The evidence is strongest for zinc, where a large review of trials found a lower risk of these infections, and moderate for Pelargonium sidoides, where bronchitis symptoms eased. The Pelargonium studies were small, though, and vitamin C showed no clear difference in infection risk.
Sources: PMID 34728441; PMID 18222667
- Supplements studied
- 11
- Medicines and peptides
- 1
- Graded outcomes
- 12
- Trials
- 7
- People studied
- 26,573
Evidence by supplement
- Strong
- Moderate
- Limited
- Very limited
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Acute Respiratory Tract Infection Risk Moderate Improvement | Improves (the measure goes down) | Moderate effect | 1 study | 5,446 people | ||
Studies that measured acute respiratory tract infection risk | ||||||
| Acute Respiratory Tract Infection Symptoms | Improves (the measure goes down) | 5,446 people | ||||
| Common Cold Risk | Changes; see studies | 5,446 people | ||||
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Bronchitis Symptoms Moderate Improvement | Improves (the measure goes down) | Moderate effect | 4 studies | 341 people | ||
Studies that measured bronchitis symptoms
| ||||||
| Common Cold Symptoms | Improves (the measure goes down) | 1 study | 1,771 people | |||
Studies that measured common cold symptoms | ||||||
| Nasal Congestion | Improves (the measure goes up) | 1 study | 1,771 people | |||
Studies that measured nasal congestion | ||||||
| Upper Respiratory Tract Infection Symptoms | Improves (the measure goes down) | 1 study | 990 people | |||
Studies that measured upper respiratory tract infection symptoms | ||||||
Vitamin D
- Asthma Symptoms: improves
- Upper Respiratory Tract Infection Risk: changes; see studies
- COPD Symptoms: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Asthma Symptoms Small Improvement | Improves (the measure goes down) | Small effect | 2 studies | 11,321 people | ||
Studies that measured asthma symptoms | ||||||
| Upper Respiratory Tract Infection Risk | Changes; see studies | 13 studies | 3,958 people | |||
Studies that measured upper respiratory tract infection risk
| ||||||
| COPD Symptoms | Improves (the measure goes down) | 11,321 people | ||||
| Lower Respiratory Tract Infection Risk | Changes; see studies | 10,993 people | ||||
Rhamnogalacturonan I
- Cold Symptom Severity: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Cold Symptom Severity A single RCT (n=146) challenged healthy volunteers with rhinovirus-16 after 8 weeks of carrot-derived RG-I supplementation (0.3 or 1.5 g/day). cRG-I significantly reduced WURSS-21 symptom scores (p<0.001) and improved quality of life measures (p<0.01) compared to placebo, with 0.3 g/day showing the strongest effects. | Improves (the measure goes down) | Moderate effect | 1 study | 146 people | ||
Vitamin C
- Upper Respiratory Tract Infection Risk
- Upper Respiratory Tract Infection Symptoms: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Upper Respiratory Tract Infection Risk No effect | NoneNo effect | 5 studies | 1,332 people | |||
Studies that measured upper respiratory tract infection risk
| ||||||
| Upper Respiratory Tract Infection Symptoms | Improves (the measure goes down) | 24 studies | 666 people | |||
Studies that measured upper respiratory tract infection symptoms | ||||||
Mitoquinone mesylate
- SARS-CoV-2 Infection Risk: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| SARS-CoV-2 Infection Risk An exploratory open-label non-randomized pilot trial (Chen et al., 2024) in 80 individuals with high-risk SARS-CoV-2 exposure found 30% infection rate with MitoQ (20 mg/day for 14 days) vs. 75% in matched controls. Supported by preclinical data (Petcherski et al., 2022, preprint) showing nanomolar antiviral potency in cell and mouse models. Non-randomized design limits conclusions. | Improves (the measure goes down) | Moderate effect | 4 studies | 80 people | ||
Studies that measured sars-cov-2 infection risk
| ||||||
Violet Flower
- Respiratory Infection Symptoms: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Respiratory Infection Symptoms A randomized double-blind controlled trial in 108 COVID-19 outpatients found that add-on violet syrup significantly improved cough (P=0.025), myalgia (P=0.036), and headache (P=0.037) over 7 days compared to standard care alone. | Improves (the measure goes down) | Small effect | 2 studies | 108 people | ||
Studies that measured respiratory infection symptoms | ||||||
Yeast Mannan
- Infection Resistance: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Infection Resistance In European sea bass, MOS feeding improved survival following pathogen challenge. A broiler chicken study demonstrated improved responses to Salmonella typhimurium challenge with dietary yeast cell wall components including MOS. Evidence is limited to animal models. | Improves (the measure goes up) | Small effect | 2 studies | |||
Echinacea
- Sleep Quality
- Upper Respiratory Tract Infection Risk: changes; see studies
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Sleep Quality No effect | NoneNo effect | 143 people | ||||
| Upper Respiratory Tract Infection Risk | Changes; see studies | 10 studies | 143 people | |||
Studies that measured upper respiratory tract infection risk
| ||||||
Slippery Elm
- Sore Throat Symptom Relief: changes; see studies
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Sore Throat Symptom Relief No controlled clinical trials specifically evaluate slippery elm for sore throat. The mucilage content provides a plausible mechanical coating/soothing mechanism, and slippery elm is a common ingredient in commercial throat lozenges, but direct clinical evidence is absent. Efficacy is inferred from traditional use and the well-characterized demulcent properties of plant mucilage. | Changes; see studies | Small effect |
Elderberry
- Upper Respiratory Tract Infection Symptoms: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Upper Respiratory Tract Infection Symptoms | Improves (the measure goes down) | 3 studies | 87 people | |||
Studies that measured upper respiratory tract infection symptoms
| ||||||
Prescription medicines and peptides studied, for context
Telavancin (Vibativ)
- Hospital-Acquired Pneumonia Efficacy
- Mortality in Renal Impairment: worsens
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Hospital-Acquired Pneumonia Efficacy ATTAIN-1 & ATTAIN-2 Phase 3: Clinical cure rates comparable to vancomycin for S. aureus HABP/VABP. FDA-approved June 2013 but indicated only when alternative treatments not suitable due to safety concerns. | NoneNo effect | 8 studies | ||||
| Mortality in Renal Impairment SAFETY CONCERN: FDA black box warning for increased mortality in patients with CrCl <50 mL/min in HABP/VABP trials. Telavancin should only be used when alternatives not suitable. Risk-benefit assessment required. | Worsens (the measure goes up) | Moderate effect | 6 studies |
Key findings
- Acute Respiratory Tract Infection RiskImproves (the measure goes down)
- Bronchitis SymptomsImproves (the measure goes down)
- Asthma SymptomsImproves (the measure goes down)
Safety notes in the studies
- An exploratory open-label non-randomized pilot trial (Chen et al., 2024) in 80 individuals with high-risk SARS-CoV-2 exposure found 30% infection rate with MitoQ (20 mg/day for 14 days) vs.
- SAFETY CONCERN: FDA black box warning for increased mortality in patients with CrCl <50 mL/min in HABP/VABP trials.
- Risk-benefit assessment required.
The Acute Respiratory Infection (ARI) Treatment Support protocol
2 primary supplements · 7 supporting supplements
- Zinc Lozenges75–100 mg total daily as lozenges (every 2–3 hours while awake)
- Pelargonium sidoides (Umckaloabo)30–60 drops or 20–30 mg extract 3× daily for 7–10 days
Shop the evidence-backed picks
The collection holds the supplements we grade A or B for its theme, in third-party tested products where the catalog has them. It opens in our Fullscript store. You can look through it without signing in; Fullscript asks for a free account to order.
Or shop one supplement
The supplements graded A or B for Acute Respiratory Infection (ARI). Each opens third-party tested products for that supplement.
- Grade A
- Grade B
We earn from purchases made in our Fullscript store, and links to Fullscript, iHerb or Thorne carry our referral, so we may earn a commission at no extra cost to you. Grades come from the research and never change based on what we earn. Full disclosure
Studies cited
2 studies from PubMed